Decision Diagnostics (OTCMKTS:DECN) vs. SpringBig (NASDAQ:SBIG) Head to Head Contrast

Decision Diagnostics (OTCMKTS:DECNGet Free Report) and SpringBig (NASDAQ:SBIGGet Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Decision Diagnostics and SpringBig, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Decision Diagnostics 0 0 0 0 0.00
SpringBig 0 0 1 0 3.00

SpringBig has a consensus target price of $1.00, suggesting a potential upside of 1,011.11%. Given SpringBig’s stronger consensus rating and higher probable upside, analysts plainly believe SpringBig is more favorable than Decision Diagnostics.

Insider & Institutional Ownership

30.9% of SpringBig shares are held by institutional investors. 41.0% of SpringBig shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Decision Diagnostics and SpringBig”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Decision Diagnostics N/A N/A N/A N/A N/A
SpringBig $28.37 million 0.15 -$10.23 million ($0.08) -1.13

Decision Diagnostics has higher earnings, but lower revenue than SpringBig.

Risk and Volatility

Decision Diagnostics has a beta of -1.77, suggesting that its share price is 277% less volatile than the S&P 500. Comparatively, SpringBig has a beta of 2.76, suggesting that its share price is 176% more volatile than the S&P 500.

Profitability

This table compares Decision Diagnostics and SpringBig’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Decision Diagnostics N/A N/A N/A
SpringBig -15.10% N/A -63.22%

Summary

SpringBig beats Decision Diagnostics on 7 of the 9 factors compared between the two stocks.

About Decision Diagnostics

(Get Free Report)

Decision Diagnostics Corp. develops smart phone based electronic medical record (EMR) technologies. The company offers prescription and non-prescription diagnostics; home testing products for the chronically ill; fulfillment services to direct to patient diabetes programs; and cell phone centric e-health products and technologies development services. It manufactures and distributes GenUltimate! glucose test strips, a Class II medical device for at-home use for the measurement of glucose; PetSure! glucose test strip for the glucose testing of dogs and cats designed to work with the Zoetis AlphaTrak and AlphaTrak II glucometers, a legacy meter; GenUltimate! 4Pets Glucose system, a proprietary glucose measuring system, including GenUltimate! 4Pets test strip and Avantage meter, for the testing of dogs, cats, and horses; and GenUltimate! Sure and GenUltimate! Precis test strips. In addition, it engages in the acquisition and holding of intellectual property including patents and trademarks and specialty manufacturing equipment. Further, the company also provides MD@Hand, an inpatient/outpatient management suite; Practice Probe, a data mining utility used to extract information from the physician's practice management system; and ResidenceWare, a residential management system that facilitates the relay of information from commercial and residential real estate management companies to occupying tenants using networking software systems and applications. Its EMR technologies are used by physicians at the point of care. The company was formerly known as InstaCare Corp. and changed its name to Decision Diagnostics Corp. in November 2011. Decision Diagnostics Corp. was founded in 2000 and is based in Westlake Village, California.

About SpringBig

(Get Free Report)

SpringBig Holdings, Inc. develops and operates a software platform that provides marketing and customer engagement services to cannabis dispensaries and brands in the United States and Canada. Its platform offers customer loyalty and marketing automation solutions. The company was founded in 2016 and is headquartered in Boca Raton, Florida.

Receive News & Ratings for Decision Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decision Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.